SLC5A2 and Myocardial fibrosis: While their mechanisms of benefit remain under investigation, preclinical studies suggest that SGLT2 inhibitors attenuate myocardial fibrosis through inhibition of TGF-β signaling, reduction in oxidative stress, and modulation of extracellular matrix remodelling [10, 11].